Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Bergmann

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Neuropharmacology|January 1, 1985
Progabide: a new GABA-mimetic agent in clinical useK J Bergmann
Advances in Neurology|January 1, 1984
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administrationC G Clough, K J Bergmann, M D Yahr
Lancet (London, England)|September 25, 1982
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administrationM D Yahr, C G Clough, K J Bergmann
Advances in Neurology|January 1, 1987
Parkinson's disease and long-term levodopa therapyK J Bergmann, M R Mendoza, M D Yahr
Der Nervenarzt|December 1, 1989
[Neuroleptic-induced akathisia]W W Fleischhacker, C H Miller, K J Bergmann
Acta Neurologica Scandinavica. Supplementum|January 1, 1983
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)M D Yahr, M R Mendoza, D Moros, et al.
Lancet (London, England)|March 10, 1984
Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonistK J Bergmann, J C Limongi, Y H Lowe, et al.
Psychopharmacology Bulletin|January 1, 1989
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisiaW W Fleischhacker, K J Bergmann, R Perovich, et al.
JAMA|November 6, 1991
Prospective study of tardive dyskinesia incidence in the elderlyB L Saltz, M G Woerner, J M Kane, et al.
Journal of Clinical Psychopharmacology|February 1, 1991
The prevalence of tardive dyskinesiaM G Woerner, J M Kane, J A Lieberman, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Neuropharmacology|January 1, 1985
Progabide: a new GABA-mimetic agent in clinical useK J Bergmann
Advances in Neurology|January 1, 1984
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administrationC G Clough, K J Bergmann, M D Yahr
Lancet (London, England)|September 25, 1982
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administrationM D Yahr, C G Clough, K J Bergmann
Advances in Neurology|January 1, 1987
Parkinson's disease and long-term levodopa therapyK J Bergmann, M R Mendoza, M D Yahr
Der Nervenarzt|December 1, 1989
[Neuroleptic-induced akathisia]W W Fleischhacker, C H Miller, K J Bergmann
Acta Neurologica Scandinavica. Supplementum|January 1, 1983
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)M D Yahr, M R Mendoza, D Moros, et al.
Lancet (London, England)|March 10, 1984
Potentiation of the "dopa" effect in parkinsonism by a direct GABA receptor agonistK J Bergmann, J C Limongi, Y H Lowe, et al.
Psychopharmacology Bulletin|January 1, 1989
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisiaW W Fleischhacker, K J Bergmann, R Perovich, et al.
JAMA|November 6, 1991
Prospective study of tardive dyskinesia incidence in the elderlyB L Saltz, M G Woerner, J M Kane, et al.
Journal of Clinical Psychopharmacology|February 1, 1991
The prevalence of tardive dyskinesiaM G Woerner, J M Kane, J A Lieberman, et al.
Pageof 1